Abstract
Although the clinical aspects of a medical device take priority in use and implementation, the business and economic aspects of the commercial device can be equally important in introduction, adoption, and perseverance. Many of these factors depend on both the physician and the medical device company. Similar to products previously introduced, vaginal mesh kits followed basic business principles, resulting in either success or failure. This chapter will review some of the business aspects of vaginal mesh kits and lessons learned during introduction, adoption, and evaluation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fenn J, Raskino M. Mastering the hype cycle: how to choose the right innovation at the right time. Boston: Harvard Business Press; 2008.
Richardson AC. Paravaginal repair. In: Benson JT, editor. Female pelvic floor disorders. New York: W.W. Norton & Co.; 1992.
Ward K, Hilton P. Minimally invasive synthetic suburethral slings: emerging complications. Obstetr Gynaecol. 2007;7(4):223–32.
U.S. Food and Drug Administration. FDA Public Health Notification. Serious complications associated with transvaginal placement of surgical mesh in repair of pelvic organ prolapse and stress urinary incontinence. 20 Oct 2008.
U.S. Food and Drug Administration. Center for Devices and Radiological Health. Urogynecologic Surgical Mesh: update on the safety and effectiveness of transvaginal placement for pelvic organ prolapse. Jul 2011.
Reynolds WS, Gold KP, Ni S, Kaufman MR, Dmochowski RR, Penson DF. Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in Medicare beneficiaries. Neurourol Urodyn. 2013;32(4):330–5.
McKinlay JB. From “promising report” to “standard procedure”: seven stages in the career of a medical innovation. Milbank Mem Fund Q Health Soc. 1981;59(3):374–411.
Wright J. Hormone replacement therapy: an example of McKinlay’s theory on the seven stages of medical innovation. J Clin Nurs. 2005;14(9):1090–7.
Bø K, Herbert RD. When and how should new therapies become routine clinical practice? Physiotherapy. 2009;95(1):51–7.
Wall LL, Brown D. The perils of commercially driven surgical innovation. Am J Obstet Gynecol. 2010;202(1):30.e1–4.
Oliveira R, Silva A, Pinto R, Silva J, Silva C, Guimarães M, et al. Short-term assessment of a tension-free vaginal tape for treating female stress urinary incontinence. BJU Int. 2009;104(2):225–8.
Solà V, Ricci P, Pardo J. Third generation sub-mid urethral mesh: experience with 110 TVT-SECUR. Arch Esp Urol. 2009;62(5):376–86.
Debodinance P, Amblard J, Lucot JP, Cosson M, Villet R, Jacquetin B. TVT Secur: prospective study and follow up at 1 year about 154 patients. J Gynecol Obstet Biol Reprod. 2009;38(4):299–303.
Meschia M, Barbacini P, Ambrogi V, Pifarotti P, Ricci L, Spreafico L. TVT-secur: a minimally invasive procedure for the treatment of primary stress urinary incontinence. One year data from a multi-centre prospective trial. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(3):313–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kohli, N. (2019). Business Aspects of Vaginal Mesh Kits: Lessons Learned. In: Shobeiri, S. (eds) The Innovation and Evolution of Medical Devices. Springer, Cham. https://doi.org/10.1007/978-3-319-97073-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-97073-8_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-97072-1
Online ISBN: 978-3-319-97073-8
eBook Packages: MedicineMedicine (R0)